Pembrolizumab, sold under the brand name Keytruda, is the immunotherapy that works best when combined with chemotherapy — and it is not particularly close. With more than 40 FDA approvals spanning at least 10 different cancer types, pembrolizumab has become the most broadly approved immunotherapy drug in history. Its combination with various chemotherapy regimens has reshaped first-line treatment for cancers ranging from non-small cell lung cancer to triple-negative breast cancer, gastric cancer, cervical cancer, and as of 2025, platinum-resistant recurrent ovarian cancer. For anyone navigating a cancer diagnosis or caring for someone who is, understanding this drug’s role matters because it has fundamentally changed what oncologists recommend as standard of care. But pembrolizumab is not the only player.
Several other checkpoint inhibitors — cemiplimab, atezolizumab, durvalumab, and newer bispecific antibodies like ivonescimab — have produced meaningful survival gains when paired with chemotherapy in specific cancers. The differences between these combinations come down to cancer type, biomarker status, and what clinical trials have demonstrated. This article covers the strongest evidence behind each major chemo-immunotherapy pairing, the cancers where these combinations have changed outcomes most dramatically, the limitations that still exist, and what recent research from 2025 and early 2026 suggests about where the field is heading. For readers of this site who are focused on brain health and dementia care, this topic matters more than you might expect. Cancer treatment decisions increasingly affect cognitive outcomes, caregiver burden, and quality of life for older adults — the same population most vulnerable to cognitive decline. Knowing which treatments offer the best survival odds with manageable side effects is part of informed caregiving.
Table of Contents
- Why Has Pembrolizumab Become the Leading Immunotherapy Paired With Chemotherapy?
- How Other Chemo-Immunotherapy Combinations Compare in Lung Cancer
- New Approvals in Stomach and Esophageal Cancer Signal a Shift
- How Newer Bispecific Antibodies Are Challenging Established Options
- The Side Effects and Cognitive Risks Caregivers Need to Know About
- A Breakthrough in Colorectal Cancer Shows What Combination Therapy Can Achieve
- What Comes Next for Chemo-Immunotherapy
- Conclusion
- Frequently Asked Questions
Why Has Pembrolizumab Become the Leading Immunotherapy Paired With Chemotherapy?
Pembrolizumab is a PD-1 checkpoint inhibitor, meaning it blocks a protein that cancer cells exploit to hide from the immune system. What sets it apart from other checkpoint inhibitors is not necessarily that it works better in head-to-head comparisons — few such comparisons exist — but that it has been tested in more clinical trials, across more cancer types, and has accumulated more regulatory approvals than any competitor. The landmark KEYNOTE-189 trial enrolled 616 patients with lung adenocarcinoma and showed that adding pembrolizumab to platinum-based chemotherapy significantly improved overall survival compared to chemotherapy alone. That trial became a blueprint for dozens of subsequent studies pairing the drug with different chemo regimens in different cancers. The breadth of pembrolizumab’s approvals creates a compounding advantage. Oncologists are familiar with it.
Treatment centers stock it. Insurance companies have established coverage pathways for it. When a new cancer type shows promise for chemo-immunotherapy, pembrolizumab is often the first checkpoint inhibitor tested because of this institutional momentum. By contrast, drugs like cemiplimab and atezolizumab, while effective, have narrower approval portfolios and fewer large-scale combination trials behind them. One of the most significant recent additions to pembrolizumab’s record came from the KEYNOTE-B96 trial in 2025, which demonstrated that pembrolizumab combined with paclitaxel — with or without bevacizumab — became the first immune checkpoint inhibitor regimen to show an overall survival benefit in all patients with platinum-resistant recurrent ovarian cancer. This was a population that had historically been extremely difficult to treat, with limited options after platinum-based chemotherapy stopped working. That approval marked a genuine turning point in gynecologic oncology.
How Other Chemo-Immunotherapy Combinations Compare in Lung Cancer
Lung cancer, particularly non-small cell lung cancer, is where chemo-immunotherapy combinations have the deepest evidence base, and it is also where the most meaningful comparisons between different immunotherapies can be made. While pembrolizumab set the standard with KEYNOTE-189, cemiplimab has produced some of the most impressive long-term data. At 60.9 months of median follow-up — one of the first five-year datasets available for chemo-immunotherapy in advanced NSCLC — cemiplimab plus chemotherapy delivered a median overall survival of 21.1 months compared to 12.9 months for chemotherapy alone. that translates to a 34 percent reduction in the risk of death, and it is the kind of long-term follow-up that gives oncologists confidence in the durability of the benefit. Atezolizumab, another PD-L1 inhibitor made by Roche, has also shown survival gains when combined with carboplatin and nab-paclitaxel in NSCLC. Overall survival reached 18.6 months compared to 13.9 months for chemotherapy alone.
These numbers are meaningful but do not quite match the cemiplimab data at extended follow-up. However, direct cross-trial comparisons are unreliable because patient populations, treatment protocols, and eligibility criteria differ. The limitation that patients and caregivers should understand is that not all NSCLC patients benefit equally from these combinations. Biomarker status — particularly PD-L1 expression levels and the presence of specific driver mutations like EGFR or ALK — determines whether chemo-immunotherapy is the right first-line approach. Patients with high PD-L1 expression may do well on immunotherapy alone, while those with targetable mutations often respond better to targeted therapies. If your oncologist recommends chemo-immunotherapy, ask specifically about PD-L1 testing and genomic profiling, because the wrong combination for the wrong molecular profile can mean side effects without proportional benefit.
New Approvals in Stomach and Esophageal Cancer Signal a Shift
One of the more important developments in late 2025 was the FDA approval of durvalumab (sold as IMFINZI) combined with chemotherapy for early-stage stomach and gastroesophageal junction cancers. Based on the MATTERHORN trial, this became the first immunotherapy approved for use both before and after surgery in these cancers — a treatment approach called perioperative therapy. The trial showed significantly improved event-free survival, meaning patients went longer without their cancer progressing, recurring, or causing death. This approval matters because stomach and esophageal cancers have historically had poor outcomes, particularly in the United States where they are often diagnosed at advanced stages.
The perioperative approach — giving immunotherapy plus chemotherapy before surgery to shrink tumors, then continuing immunotherapy after surgery to reduce recurrence risk — represents a philosophical shift in how oncologists think about combining these treatments. Rather than reserving immunotherapy for patients whose cancer has already spread, the MATTERHORN data supports using it earlier to prevent spread in the first place. For older adults, gastric and esophageal cancers are disproportionately common, and treatment decisions in this population must weigh survival benefit against functional decline and cognitive impact. The perioperative approach adds months of treatment, and immune-related side effects — which can include neurological complications like encephalitis in rare cases — are important to discuss with the care team, especially for patients already managing cognitive concerns.
How Newer Bispecific Antibodies Are Challenging Established Options
The chemo-immunotherapy landscape is not static. A newer class of drugs called bispecific antibodies is beginning to show results that could eventually challenge pembrolizumab’s dominance in specific settings. The most notable example is ivonescimab, a bispecific antibody that simultaneously targets both PD-1 and VEGF — essentially combining an immune checkpoint inhibitor and an anti-angiogenic drug into a single molecule. Data presented at ASCO 2025 showed that ivonescimab combined with chemotherapy improved progression-free survival to 11.1 months compared to 6.9 months for chemotherapy plus tislelizumab in patients with squamous NSCLC. The objective response rate was also higher at 76 percent versus 67 percent. The tradeoff with bispecific antibodies is complexity.
These are engineered molecules that interact with multiple biological pathways simultaneously, which can mean a different side effect profile compared to single-target checkpoint inhibitors. Anti-VEGF activity, for instance, carries risks of hypertension, bleeding, and wound healing complications that pure PD-1 inhibitors do not. For patients who are surgical candidates or who have pre-existing cardiovascular issues — common in older adults — this tradeoff requires careful evaluation. There is also the question of access and cost. Bispecific antibodies are newer, less widely available, and may not yet be covered by all insurance plans. Pembrolizumab, by contrast, has the benefit of years of real-world use, established dosing protocols, and well-understood management strategies for its side effects. For now, the practical reality is that pembrolizumab-based combinations remain the default in most treatment centers, while bispecific antibodies represent a promising but still maturing option.
The Side Effects and Cognitive Risks Caregivers Need to Know About
Chemo-immunotherapy combinations are more effective than chemotherapy alone, but they are also more toxic. Combining two classes of drugs means patients face side effects from both — the traditional nausea, fatigue, and blood count drops from chemotherapy, plus the immune-related adverse events from immunotherapy. These immune-related side effects occur because checkpoint inhibitors do not just unleash the immune system against cancer; they can also trigger autoimmune attacks against healthy organs. Thyroid dysfunction, skin rashes, colitis, hepatitis, and pneumonitis are among the more common complications. For readers of this site, the neurological side effects deserve particular attention.
Immune-related encephalitis, peripheral neuropathy, and myasthenia gravis-like syndromes are rare but documented complications of checkpoint inhibitors. In older patients who may already have mild cognitive impairment or early-stage dementia, these neurological side effects can be difficult to distinguish from disease progression. Caregivers should establish a clear cognitive baseline before treatment begins and report any sudden changes in confusion, memory, personality, or motor function to the oncology team immediately — do not assume it is just the cancer or just aging. A further limitation is that immune-related side effects can be delayed, sometimes appearing weeks or months after treatment ends. This creates a monitoring burden that falls heavily on caregivers, particularly for patients living at home. Ask the oncology team for a written list of warning signs specific to the immunotherapy being used, and make sure every caregiver in the household has a copy.
A Breakthrough in Colorectal Cancer Shows What Combination Therapy Can Achieve
Advanced metastatic colorectal cancer has historically been resistant to immunotherapy, which makes the results from a recent combination study worth noting. When atezolizumab was combined with mFOLFOX6 chemotherapy and bevacizumab, median progression-free survival reached 30 months — compared to just 4.3 months for immunotherapy alone. That sevenfold difference illustrates why the combination approach matters so much in cancers where immunotherapy by itself has limited activity.
This finding reinforces a broader principle in oncology: the right drug in the wrong context can look ineffective. Immunotherapy alone was nearly useless in this colorectal cancer population, but when chemotherapy was added — possibly by causing cancer cell death that released tumor antigens, priming the immune system — the results were transformed. It is a reminder that treatment failures with single agents do not always mean the drug does not work; sometimes it means the drug needs a partner.
What Comes Next for Chemo-Immunotherapy
Research announced on March 17, 2026, by UT Austin scientists described an experimental chemotherapy drug that may trick the immune system into fighting cancer — potentially opening an entirely new class of chemo-immunotherapy combinations. Unlike current approaches where chemotherapy and immunotherapy are separate drugs administered together, this research suggests that a single chemotherapy agent could be designed to inherently activate immune responses. If this approach pans out in clinical trials, it could simplify treatment regimens, reduce the number of infusions patients need, and potentially lower the rate of immune-related side effects by making the immune activation more targeted.
The broader trajectory is clear. Chemo-immunotherapy has moved from experimental to standard of care in less than a decade, and the combinations are getting more sophisticated. Bispecific antibodies, perioperative strategies, and immune-activating chemotherapy agents all point toward a future where the line between chemotherapy and immunotherapy blurs further. For patients and caregivers making treatment decisions today, the practical takeaway is that pembrolizumab combined with chemotherapy remains the most broadly supported option, but the field is moving quickly enough that second opinions from academic cancer centers — where newer combinations may be available through clinical trials — are always worth pursuing.
Conclusion
Pembrolizumab stands as the immunotherapy with the strongest and broadest evidence for combination with chemotherapy, with approvals across more than 10 cancer types and landmark trial results in lung, ovarian, and other cancers. But it is not the only option worth knowing about. Cemiplimab has produced impressive five-year survival data in lung cancer, durvalumab has opened new treatment windows in stomach cancer, and bispecific antibodies like ivonescimab represent the next wave of innovation.
The chemo-immunotherapy approach has become standard of care for first-line treatment in multiple cancers as of 2026. For caregivers managing the intersection of cancer treatment and cognitive health, the key priorities are establishing cognitive baselines before treatment, understanding the neurological side effects specific to checkpoint inhibitors, and maintaining close communication with the oncology team about any changes in mental status. Ask about biomarker testing to ensure the right combination is being chosen, inquire about clinical trials at academic centers, and do not hesitate to seek a second opinion. These combinations save lives, but they require informed, vigilant caregiving to navigate safely.
Frequently Asked Questions
What is chemo-immunotherapy?
Chemo-immunotherapy is a treatment approach that combines traditional chemotherapy drugs with immunotherapy drugs — most commonly checkpoint inhibitors like pembrolizumab. The chemotherapy kills cancer cells directly and may also help expose the cancer to the immune system, while the immunotherapy removes the brakes that cancer cells use to hide from immune attack. Together, they often produce better outcomes than either approach alone.
Is pembrolizumab the same as Keytruda?
Yes. Pembrolizumab is the generic name and Keytruda is the brand name, both referring to the same PD-1 checkpoint inhibitor made by Merck. It has received more than 40 FDA approvals across multiple cancer types, making it the most widely approved immunotherapy in history.
Can chemo-immunotherapy cause cognitive problems?
Checkpoint inhibitors can cause rare but serious neurological side effects including encephalitis, neuropathy, and confusion. These effects can be difficult to distinguish from cognitive decline in patients who already have mild impairment or early dementia. Any sudden change in memory, behavior, or mental clarity during or after treatment should be reported to the oncology team immediately.
Does every cancer patient benefit from chemo-immunotherapy?
No. The benefit depends on cancer type, stage, biomarker status including PD-L1 expression, and whether specific genetic mutations are present. Patients with certain driver mutations in lung cancer, for example, may respond better to targeted therapies than to chemo-immunotherapy. Comprehensive genomic profiling helps determine the best approach.
What is the newest chemo-immunotherapy approval?
One of the most recent notable approvals is durvalumab combined with chemotherapy for early-stage stomach and gastroesophageal junction cancers, approved by the FDA in November 2025 based on the MATTERHORN trial. The pembrolizumab combination for platinum-resistant ovarian cancer, approved in 2025, was also a significant milestone.
